V
Vincent Hurez
Researcher at University of Texas at Austin
Publications - 57
Citations - 2939
Vincent Hurez is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 27, co-authored 57 publications receiving 2608 citations. Previous affiliations of Vincent Hurez include French Institute of Health and Medical Research & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
Julie Di Paolo,Tao Huang,Mercedesz Balazs,James Barbosa,James Barbosa,Kai H. Barck,Brandon J. Bravo,Richard A.D. Carano,James W. Darrow,Douglas R. Davies,Laura DeForge,Lauri Diehl,Ronald E. Ferrando,Steven L. Gallion,Anthony M. Giannetti,Peter Gribling,Vincent Hurez,Vincent Hurez,Sarah G. Hymowitz,Randall Mark Jones,Kropf Jeffrey E,Wyne P. Lee,Patricia Maciejewski,Scott A. Mitchell,Hong Rong,Bart L. Staker,J. Andrew Whitney,Sherry Yeh,Wendy B. Young,Christine Yu,Juan Zhang,Karin Reif,Kevin S. Currie +32 more
TL;DR: CGI1746 is described, a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation that decreases cytokine levels within joints and ameliorates disease.
Journal ArticleDOI
Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma
Curtis A. Clark,Harshita Gupta,Gangadhara R. Sareddy,Srilakshmi Pandeswara,Shunhua Lao,Bin Yuan,Justin M. Drerup,Alvaro Padron,Jose R. Conejo-Garcia,Kruthi Murthy,Yang Liu,Yang Liu,Mary Jo Turk,Kathrin Thedieck,Vincent Hurez,Rong Li,Ratna K. Vadlamudi,Tyler J. Curiel +17 more
TL;DR: Understanding of PD-L1 functions is extended, nonimmune effects of anti-PD-L 1 immunotherapy are illustrated, and broader uses for PD- L1 as a biomarker for assessing cancer therapeutic responses are suggested.
Journal ArticleDOI
V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig).
Michel D. Kazatchkine,Gilles Dietrich,Vincent Hurez,Nicoletta Ronda,B. Bellon,F. Rossi,Srinivas V. Kaveri +6 more
TL;DR: In addition to its use as substitute therapy for primary and secondary immunodeficiencies, intravenous immunoglobulin (i.v.Ig) is increasingly being used as an immunomodulating therapy in the treatment of patients with a variety of autoimmune and systemic inflammatory disorders.
Journal ArticleDOI
Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.
Srini V. Kaveri,Tchavdar L. Vassilev,Vincent Hurez,R Lengagne,C. Lefranc,S Cot,P Pouletty,D Glotz,M. D. Kazatchkine +8 more
TL;DR: It is reported here that IVIg recognizes the B07.75-84 peptide, corresponding to a conserved region of the alpha I helix of the first domain of HLA-B7 01, which represents a nonpolymorphic determinant of Hla class I molecules.
Journal ArticleDOI
Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.
TL;DR: The current use of IVIg in human autoimmune diseases is discussed with a particular emphasis on the possible mechanisms by whichIVIg could suppress pathological autoimmune responses.